Company intelligence / Profile preview
Compass Therapeutics, Inc.
Boston, Massachusetts, United Statescompasstherapeutics.com ↗
- Ownership
- Public · CMPX
- Employees
- ~65
- Development stage
- Phase 2
01
Overview
Compass Therapeutics is advancing tovecimig (CTX-009) in a Phase 2/3 trial for biliary tract cancer with top-line data expected in Q1 2025. The company recently presented data on enhanced efficacy of CTX-471 in combination with tovecimig in checkpoint-refractory models at AACR Annual Meeting in April 2025. They are also developing CTX-10726, a novel PD-1 x VEGF-A bispecific antibody with IND submission expected by end of 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-based therapeuticsMonoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
The University of Texas MD Anderson Cancer Center
04
Financials
- Market cap
- $369.2M
- Total revenue
- $0
- Enterprise value
- $198.9M
Beyond the preview
Go deeper on Compass Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compass Therapeutics, Inc..